Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
DUBLIN, Ireland, April 18, 2017 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2017 on Thursday, April 27, 2017. The Company has scheduled a conference call for that same day, Thursday, April 27, 2017 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 |
| International: | 1-412-317-6581 |
| Conference ID #: | 10105671 |
A simultaneous webcast of the call can be accessed at: https://www.webcaster4.com/Webcast/Page/1135/20749
A replay of the call can be accessed until May 4, 2017 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10105671 |
The webcast of the call will be available for 30 days at: https://www.webcaster4.com/Webcast/Page/1135/20749
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Contact Kevin Tansley Trinity Biotech plc (353)-1-2769800 E-mail: [email protected] Joe Diaz, Joe Dorame and Robert Blum Lytham Partners, LLC Investor Relations 602-889-9700
